Sanofi-Aventis Buying Fovea Pharma for €370 Million
Sanofi-Aventis has agreed to acquire Fovea Pharmaceuticals SA, a Paris, France-based drug company focused on ophthalmic diseases. The deal is valued at up to €370 million, including an upfront payment and possible milestone payments. Fovea had raised over $60 million in VC funding from firms like Forbion Capital Partners, Sofinnova Partners, Abingworth, GIMV, The Wellcome Trust and CAPE.
1 October 2009•2 mins read
